Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell–like phenotype

Toward Minimal Residual Disease-Directed Therapy in Melanoma

(2018) Florian Rambow et al.   CELL

PI3K Positively Regulates YAP and TAZ in Mammary Tumorigenesis Through Multiple Signaling Pathways

(2018) Yulei Zhao et al.   MOLECULAR CANCER RESEARCH

Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy

(2018) Anuja Sathe et al.   PLoS One

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer

(2018) Khyati N. Shah et al.   NATURE MEDICINE

A single-cell survey of the small intestinal epithelium

(2017) Adam L. Haber et al.   NATURE

Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer

(2017) Claudio Isella et al.   Nature Communications

Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation

(2017) Chunying Song et al.   Cancer Discovery

Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer

(2017) Min Zou et al.   Cancer Discovery

Rebound Effects Caused by Withdrawal of MET Kinase Inhibitor Are Quenched by a MET Therapeutic Antibody

(2016) E. Pupo et al.   CANCER RESEARCH

A Landscape of Pharmacogenomic Interactions in Cancer

(2016) Francesco Iorio et al.   CELL

A framework for understanding and targeting residual disease in oncogene-driven solid cancers

(2016) Trever G Bivona et al.   NATURE MEDICINE

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

(2016) Aaron N Hata et al.   NATURE MEDICINE

Reg4+deep crypt secretory cells function as epithelial niche for Lgr5+stem cells in colon

(2016) Nobuo Sasaki et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

EpiMINE, a computational program for mining epigenomic data

(2016) SriGanesh Jammula et al.   Epigenetics & Chromatin

Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells

(2016) Michael Ramirez et al.   Nature Communications

Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells

(2016) Albert Bosch-Vilaró et al.   Oncotarget

Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas

(2015) S. M. Leto et al.   CLINICAL CANCER RESEARCH

Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity

(2015) H. J. Jacobsen et al.   CLINICAL CANCER RESEARCH

Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses

(2015) Gideon M. Blumenthal et al.   JOURNAL OF CLINICAL ONCOLOGY

The genomic landscape of response to EGFR blockade in colorectal cancer

(2015) Andrea Bertotti et al.   NATURE

Yap-dependent reprogramming of Lgr5+ stem cells drives intestinal regeneration and cancer

(2015) Alex Gregorieff et al.   NATURE

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

(2015) Luping Lin et al.   NATURE GENETICS

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer

(2015) Gorjan Hrustanovic et al.   NATURE MEDICINE

Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer

(2015) Maicol Mancini et al.   Science Signaling

IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies

(2015) Eugenia R. Zanella et al.   Science Translational Medicine

Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers

(2015) Sandra Misale et al.   Nature Communications

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer

(2015) R. Dienstmann et al.   Cancer Discovery

HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment

(2015) S. M. Kavuri et al.   Cancer Discovery

Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer

(2015) Maicol Mancini et al.   Science Signaling

MET Signaling in Colon Cancer Stem-like Cells Blunts the Therapeutic Response to EGFR Inhibitors

(2014) Paolo Luraghi et al.   CANCER RESEARCH

Molecular Pathways: HER3 Targeted Therapy

(2014) K. Gala et al.   CLINICAL CANCER RESEARCH

Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function

(2014) Andrea Viale et al.   NATURE

Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3

(2014) Chong Sun et al.   Cell Reports

Paneth Cells: Maestros of the Small Intestinal Crypts

(2013) Hans C. Clevers et al.   Annual Review of Physiology

Regulation of Hippo Signaling by EGFR-MAPK Signaling through Ajuba Family Proteins

(2013) B.V.V.G. Reddy et al.   DEVELOPMENTAL CELL

Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated With Cetuximab

(2013) Hubert Piessevaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Intestinal label-retaining cells are secretory precursors expressing Lgr5

(2013) Simon J. A. Buczacki et al.   NATURE

A unifying theory for the crypt

(2013) Hans Clevers   NATURE

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

(2013) Jean-Yves Douillard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor growth dynamics: insights into evolutionary processes

(2013) Ignacio A. Rodriguez-Brenes et al.   TRENDS IN ECOLOGY & EVOLUTION

Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer

(2013) Alberto Bardelli et al.   Cancer Discovery

Identifying the Stem Cell of the Intestinal Crypt: Strategies and Pitfalls

(2012) Nick Barker et al.   Cell Stem Cell

LAS: A Software Platform to Support Oncological Data Management

(2012) Elena Baralis et al.   JOURNAL OF MEDICAL SYSTEMS

An integrated encyclopedia of DNA elements in the human genome

(2012)   NATURE

AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity

(2011) Sarat Chandarlapaty et al.   CANCER CELL

Role of YAP/TAZ in mechanotransduction

(2011) Sirio Dupont et al.   NATURE

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

(2011) K. Yonesaka et al.   Science Translational Medicine

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer

(2011) A. Bertotti et al.   Cancer Discovery

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

(2010) Sreenath V. Sharma et al.   CELL

Inhibition of NF-κB Signaling by Quinacrine Is Cytotoxic to Human Colon Carcinoma Cell Lines and Is Synergistic in Combination with Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) or Oxaliplatin

(2010) Tanvi S. Jani et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

(2010) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL INVESTIGATION

Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial)

(2009) H. Piessevaux et al.   ANNALS OF ONCOLOGY

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

(2008) J. Tsai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA